Compare GTIM & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | HSCS |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | 2078 | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 15.8M |
| IPO Year | 2013 | 2022 |
| Metric | GTIM | HSCS |
|---|---|---|
| Price | $1.51 | $4.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.0K | ★ 145.5K |
| Earning Date | 08-06-2026 | 09-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.84 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $142,315,000.00 | $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | N/A | $18,321.05 |
| P/E Ratio | $7.14 | ★ N/A |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $1.10 | $1.63 |
| 52 Week High | $2.09 | $5.25 |
| Indicator | GTIM | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 58.35 |
| Support Level | $1.44 | $1.84 |
| Resistance Level | $1.52 | $5.25 |
| Average True Range (ATR) | 0.05 | 0.51 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 42.86 | 61.50 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.